in vitro News and Research

RSS

Sunshine Biopharma completes Adva-27a cytotoxicity study on multidrug-resistant lung cancer

Sunshine Biopharma Inc., a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has completed a cytotoxicity study of its lead compound, Adva-27a, in H69AR, a Multidrug Resistant Small Cell Lung Cancer cell line. Cytotoxicity studies measure the ability of a drug to destroy cancer cells in vitro.

27 Jun 2012

RXi Pharmaceuticals initiates RXI-109 Phase 1 trial to reduce surgical scars

RXi Pharmaceuticals Corporation today announced that it successfully initiated its first ever clinical study with an RNAi compound, RXI-109, using their proprietary self-delivering RNAi technology.

27 Jun 2012

HemoGenix receives first Master File Number from FDA CBER for HALO-96 PQR

HemoGenix announced today that FDA CBER has given HemoGenix its first Master File Number for an in vitro blood stem cell potency, quality and release assay (HALO-96 PQR) for cellular therapy products used for stem cell transplantation purposes. HALO-96 PQR is the first commercially available stem cell potency assay for cellular therapy products.

27 Jun 2012

Study: Fertility drug-conceived children are shorter on average

Among children born full term, those conceived with the help of fertility drugs are slightly shorter than naturally conceived children but overall are physically healthy, a new study finds. Results of the study will be presented Saturday at The Endocrine Society's 94th Annual Meeting in Houston.

26 Jun 2012

Teleflex announces acquisition of Semprus BioSciences

Teleflex Incorporated, a leading global provider of medical devices for critical care and surgery, announced it has acquired Semprus BioSciences, a biomedical company and spin out from Massachusetts Institute of Technology.

25 Jun 2012

Skin infections in AD patients linked to PMN impairment

Impairment of polymorphonuclear granulocytes among patients with atopic dermatitis may represent an additional cause of skin infections, suggest study findings.

22 Jun 2012

UC3M joins European research project on tuberculosis treatments

Scientists at the Carlos III University in Madrid (UC3M) are participating in a European research project designed to study tuberculosis treatments. The objective of the study is to improve diagnostic imaging technology in order to help develop new drugs to treat the disease.

22 Jun 2012

Selenium reduces Staph populations in medical implants

Selenium is an inexpensive element that naturally belongs in the body. It is also known to combat bacteria. Still, it had not been tried as an antibiotic coating on a medical device material. In a new study, Brown University engineers report that when they used selenium nanoparticles to coat polycarbonate, the material of catheters and endotracheal tubes, the results were significant reductions in cultured populations of Staphylococcus aureus bacteria, sometimes by as much as 90 percent.

22 Jun 2012

MAQUET's INTERGARD SYNERGY vascular graft receives CE mark

MAQUET Cardiovascular, LLC announced today that it has received CE mark for its INTERGARD SYNERGY vascular graft. This graft represents the next generation in antimicrobial grafts combining the well-known antimicrobial properties of silver acetate and triclosan.

19 Jun 2012

LDL particles may be a more accurate measure of early-stage atherosclerosis

LipoScience, Inc., today announced publication of a clinical study in the current issue of Atherosclerosis suggesting that low density lipoprotein (LDL) particles may be a more accurate measure of early-stage (subclinical) atherosclerosis than LDL cholesterol among retired National Football League (NFL) players.

19 Jun 2012

Life Technologies introduces three next generation genetic engineering kits

Life Technologies Corporation today announced the launch of three next generation GeneArt genetic engineering kits that allow molecular and synthetic biologists unprecedented speed, flexibility, precision, and efficiency for the seamless cloning, assembly, and editing of genetic material.

19 Jun 2012

Researchers identify commensal bacteria in the human intestine

Researchers at Baylor College of Medicine and Texas Children's Hospital have identified commensal bacteria in the human intestine that produce a neurotransmitter that may play a role in preventing or treating inflammatory bowel diseases such as Crohn's disease.

18 Jun 2012

New methods show signs of promise for successful IVF treatments

The success rate of in vitro fertilization (IVF) procedures still remains relatively low, at only around 30%. The high emotional, health and financial costs associated with having to undergo the procedure multiple times has driven the need to develop more efficient methods of assessing the development potential of embryos to ensure that only those with the highest potential are selected for IVF treatment.

13 Jun 2012

Long-lasting weekly fertility injections work as well as daily

New long-lasting weekly injections of fertility hormones are as safe and effective as standard daily injections, according to Cochrane researchers. The researchers compared weekly and daily hormone injections in a Cochrane systematic review and found no difference in pregnancies or serious side effects between the two regimens.

13 Jun 2012

IVF linked to increased relapse rate among MS patients

In vitro fertilisation (IVF) is linked to an increased rate of relapse among women with multiple sclerosis (MS), suggests a small study published online in the Journal of Neurology Neurosurgery and Psychiatry.

12 Jun 2012

MVP receives European patent for PEG conjugates of interferon-beta-1b to treat MS

Mountain View Pharmaceuticals, Inc. announced its receipt of European Patent No. 1 667 708 B1, titled "Polyethylene Glycol Conjugates of Interferon-beta-1b with Enhanced in vitro Biological Potency."

12 Jun 2012

Ampio’s CRO completes Optina clinical trial for DME

Ampio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, whose lead drugs treat inflammatory diseases, including osteoarthritis and complications of Diabetes Mellitus such as diabetic macular edema (and others) announced today that it's CRO has completed analysis of the primary end point in the Optina clinical trial for DME conducted at St Michael Diabetes Hospital in Toronto Canada.

11 Jun 2012

Genes ‘choose only good eggs’ for IVF

Researchers have identified a technique that could help them “pick the right egg” for in vitro fertilization treatment.

8 Jun 2012

Banyan, Amarantus complete collaboration agreement related to TBI development program

Amarantus BioSciences, Inc., a biotechnology company developing new treatments for brain-related disorders including traumatic brain injury (TBI) based on its proprietary anti-apoptotic therapeutic protein known as MANF and Banyan Biomarkers, the leader in developing in vitro diagnostic products to detect TBI, today announced the successful completion of a collaboration agreement initiated in November 2011 to evaluate MANF's potential as a disease-modifying agent for the treatment of TBI.

8 Jun 2012

Roche files TnT-hs assay 510(k) submission with FDA for use on laboratory analyzers

Roche announced today that it has filed a 510(k) submission to the U.S. Food and Drug Administration (FDA) for a fully automated TnT-hs assay for use on Roche's full portfolio of laboratory analyzers.

From Roche Sequencing and Life Science 8 Jun 2012